UroGen's Lead Product Data Back Barrett's Interest

UroGen's reverse thermal gel formulation of mitomycin produced a high rate of complete responses in patients with urothelial cancer; developing a commercialization strategy for the product will benefit from the experience of the company's new CEO.  

HumanBladder
It is difficult to resect tumors located in the pelvic region • Source: Shutterstock

New York-based biotech UroGen Pharma Ltd. reported positive top-line Phase III clinical results with its lead compound, UGN-101 (mitomycin gel, 0.4%), in patients with low-grade upper tract urothelial cancer on Jan. 8, just under a week after the high-profile appointment of Liz Barrett as its president and CEO, and two days before a company presentation at the J.P. Morgan Healthcare Conference.

Upper tract (renal pelvis, ureter) urothelial carcinomas comprise about 5%-10% of all urothelial carcinomas, which can arise along any part...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category